share_log

T2 Biosystems | 8-K: Entered into an Equity Distribution Agreement

T2 Biosystems | 8-K: Entered into an Equity Distribution Agreement

T2 Biosystems | 8-K:簽訂股權分銷協議
美股SEC公告 ·  2024/07/20 04:21

Moomoo AI 已提取核心訊息

T2 Biosystems announced the termination of its Equity Distribution Agreement with Canaccord Genuity LLC on July 19, 2024. The agreement, originally established on March 31, 2021, had enabled the company to sell shares of its common stock through an "at the market" equity offering program with Canaccord acting as sales agent.The company confirmed that no termination penalties are associated with ending the agreement. The termination was executed in accordance with the terms outlined in the original agreement, which was previously filed as Exhibit 1.2 to the Company's Registration Statement on Form S-3 with the SEC on March 31, 2021.
T2 Biosystems announced the termination of its Equity Distribution Agreement with Canaccord Genuity LLC on July 19, 2024. The agreement, originally established on March 31, 2021, had enabled the company to sell shares of its common stock through an "at the market" equity offering program with Canaccord acting as sales agent.The company confirmed that no termination penalties are associated with ending the agreement. The termination was executed in accordance with the terms outlined in the original agreement, which was previously filed as Exhibit 1.2 to the Company's Registration Statement on Form S-3 with the SEC on March 31, 2021.
T2 Biosystems於2024年7月19日宣佈終止與Canaccord Genuity LLC的股權分配協議。該協議最初於2021年3月31日建立,使公司能夠通過市場報價計劃出售其普通股,Canaccord作爲銷售代理。 公司確認沒有與終止協議相關的罰金。終止是根據原始協議中規定的條款執行的,該協議在2021年3月31日作爲公司S-3表格註冊聲明的附件1.2提交給SEC。
T2 Biosystems於2024年7月19日宣佈終止與Canaccord Genuity LLC的股權分配協議。該協議最初於2021年3月31日建立,使公司能夠通過市場報價計劃出售其普通股,Canaccord作爲銷售代理。 公司確認沒有與終止協議相關的罰金。終止是根據原始協議中規定的條款執行的,該協議在2021年3月31日作爲公司S-3表格註冊聲明的附件1.2提交給SEC。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息